An experimental treatment greatly reduced the risk of hospitalization and emergency room visits in people who contracted COVID-19, according to the maker of the drug and investigators running a clinical trial.
California-based Eiger BioPharmaceuticals and investigators running the TOGETHER trial say (pdf) that the treatment, Peginterferon Lambda, cut the risk of needing hospital care by 50 percent and death by 60 percent in a phase 3 trial measuring the results through the 28th day after receiving the treatment.
